Nuvigil reduces need for sleep

Nuvigil is a stimulant (analeptic), which is taken by the treatment of narcolepsy.

The main effect of the drug is the reduced need for sleep. Probably it has also a neuroprotective effect. There is studied the effectiveness of the medication by the cognitive disorders (related with attention) in the structure of schizophrenia (efficacy by schizophrenia is also associated with the stimulation of D1 dopamine receptors). Patients can easily buy Nuvigil at any drugstore or order Nuvigil via Internet.

Antidepressant properties of Generic Nuvigil (Armodafinil) are studied in the therapy by bipolar affective disorder (it is most often used as an additional agent in the treatment regimen). Predictor of the effectiveness of the drug by depression is a decrease of the energy potential in the structure of the disease. There is also studied its efficiency at various addictions (it is assumed that, except for compensation for the effects of the abolition of stimulants, the medication may help control impulsivity by alcoholism).

The drug is considered as an opportunity corrector of unwanted sedation associated with taking antipsychotic, but there is a possibility of deterioration of psychotic symptoms. The medication has not been approved, but used to reduce neurological symptoms of fatigue by multiple sclerosis. The patients followed the standard dose or took a dose of 200-400 mg at the start of the day, which, they assumed, would be tedious for them.

In 2000, the company Cephalon conducted a research for evaluating the possibility of the usage of the drug as a potential agent by the treatment of fatigue associated with multiple sclerosis. A group of seventy two volunteers with different degrees of severity of the disease took two different doses of the drug and placebo for 9 weeks. The level of fatigue was assessed by the patients on a standardized scale. The patients who took a lower dose of the drug felt less tired and there was set a significant difference between the levels of fatigue by those who took the lower dose of the medication in comparison to those who took a placebo.

A large dose of the drug showed no significantly greater effect.   In December 2004, the company Cephalon introduced a new drug under the name Sparlon. Brand tablets were containing a high dose of Nuvigil for usage by the treatment of Attention Deficit Hyperactivity Disorder by children and adolescents aged from 6 to 17 years. Although the studies showed positive results, the advisory committee of the Office of the Food and Drug Administration voted 12 to 1 against the drug's approval, citing the incidence of reactions such as skin rash in the research, which included 933 patients, including also two serious cases that were known as multiform erythema and Stevens-Johnson syndrome.